At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
STSP-0601 for Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II,Multi-center, Open, Multiple-dose Design to Evaluate the Safety,Tolerability and Efficacy of STSP-0601 for Injection in Patients With Inhibitory Hemophilia
Staidson (Beijing) Biopharmaceuticals Co., Ltd·interventional·Posted Aug 30, 2021·Updated Sep 19, 2024
In Brief
A Phase 2 clinical trial evaluating STSP-0601 for Injection for Hemophilia. Completed, enrolled 77 participants across 1 site.
Detailed Summary
This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartOct 2021
Primary CompletionJul 2023
Study CompletionJul 2023
TodayJul 2026
First PostedAug 30, 2021
Enrollment StartOct 12, 2021
Primary CompletionJul 15, 2023
Study CompletionJul 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.8 years ago
Interventions
STSP-0601 for Injectiondrug
A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
STSP-0601 for Injectiondrug
A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia